Development of high-throughput screening assays for detecting early gastric cancer: translating proteomics research into clinical outcomes using emerging mass spectrometry and photonics technologies

胃癌(GC)是全球第二大癌症死亡原因，1996-2006年间夺走了11,000名澳大利亚人的生命。被诊断为GC的患者预计5年存活率为10%-30%。如果在疾病的早期阶段发现病例，治疗更有效，这种情况可能会得到改善。来自阿德莱德和墨尔本的研究人员正在开发一种早期GC的诊断方法，这种方法基于一种只需要一滴血的新型检测系统。

Gastric cancer (GC) is the second leading cause of cancer death worldwide, claiming the lives of >11,000 Australians from 1996-2006. Individuals diagnosed with GC have an expected 5-year survival rate of 10-30%. This could be improved if cases were identified in the early stages of the disease where treatments are more effective. Researchers from Adelaide and Melbourne are developing a diagnostic assay for early-stage GC based on a novel detection system that requires only a drop of blood.